Expression of Benign and Malignant Thyroid Tissue in Ovarian Teratomas and the Importance of Multimodal Management as Illustrated by a <i>BRAF</i>-Positive Follicular Variant of Papillary Thyroid Cancer

Wolff, E; Hughes, Marybeth S.; Merino, María J.; Reynolds, James C.; Davis, Jeremy L.; Cochran, Craig; Celi, Francesco S.

doi:10.1089/thy.2009.0458

Cited by 45 publications

(41 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BRAF MUTATIONS IN THYROID CANCER ARISING FROM OVARIAN TERATOMAS Papillary thyroid carcinoma can arise from ovarian teratoma. This rare cancer is associated with alterations in the MAPK pathway including point mutations in BRAF [38][39][40]. These carcinomas are rare and BRAF mutations have been studied in less than 10 reports.…”

mentioning

confidence: 99%

Clinicopathological relevance of BRAF mutations in human cancer

et al. 2013

View full text Add to dashboard Cite

mentioning

confidence: 99%

Clinicopathological relevance of BRAF mutations in human cancer

et al. 2013

View full text Add to dashboard Cite

“…As shown in the literature (18), up to 20% of ovarian teratomas contain thyroid tissue, and 5% of them are struma ovarii, defined as the tumour being more than half thyroid tissue (18,19). Struma ovarii represent an uncommon but well known false-positive localization of 131 I (20)(21)(22), because it is mainly or exclusively composed of well-differentiated and functioning thyroid tissue, able to trap iodine as well as to produce thyroid hormones and thyroglobylin (18)(19)(20)(21)(22). Up to date, there are only four reports in the literature of radioiodine uptake by ovarian dermoid cysts, not be classified as struma ovarii (23)(24)(25)(26).…”

Section: Discussionmentioning

confidence: 69%

“…Typical dermoid cysts are epithelial--lined cavities with skin appendages, including hair, hair follicles, sebaceous material, deriving from ectodermal tissue. They may also contain mesodermal tissue (bone, teeth…), and tissue of endodermal origin, including well differentiated thyroid tissue (18). Dermoid cysts primarily occur in the gonads, mostly in female patients.…”

Section: Discussionmentioning

confidence: 99%

Abnormal radioiodine uptake on post-therapy whole body scan and sodium/iodine symporter expression in a dermoid cyst of the ovary: report of a case and review of the literature

Campennì

Giovinazzo

Tuccari

et al. 2015

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

SUMMARYIn patients affected by differentiated thyroid cancer, the whole-body scan (WBS) with 131-radioiodine, especially when performed after a therapeutic activity of 131 I, represents a sensitive procedure for detecting thyroid remnant and/or metastatic disease. Nevertheless, a wide spectrum of potentially pitfalls has been reported. Herein we describe a 63-year-old woman affected by follicular thyroid cancer, who was accidentally found to have an abdominal mass at post-dose WBS (pWBS). pWBS showed abnormal radioiodine uptake in the upper mediastinum, consistent with lymph-node metastases, and a slight radioiodine uptake in an abdominal focal area. Computed tomography revealed an inhomogeneous mass in the pelvis, previously unrecognized. The lesion, surgically removed, was found to be a typical dermoid cyst of the ovary, without any evidence of thyroid tissue. By immunohistochemistry, a moderate expression of the sodium-iodine symporter (NIS) was demonstrated in the epithelial cells, suggesting a NIS-dependent uptake of radioiodine by the cyst. Arch Endocrinol Metab.2015;59(4):351-4

show abstract

“…An A→G transversion at exon 15 nucleotide 1801 (A1801G) of the BRAF gene resulted in the replacement of lysine with glutamic acid at position 601 (BRAF K601E), which was also a heterozygous mutation in this patient. Trovisco et al (14) first reported the BRAF K601E mutation in a PTC patient in 2005, and 18 additional cases have been subsequently described (15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Meta-analysis demonstrated that the BRAF K601E mutation was predominantly identified in FV-PTC, followed by FTC and PTC, and only one case of TA had the BRAF K601E mutation.…”

Section: Discussionmentioning

confidence: 99%

“…Meta-analysis demonstrated that the BRAF K601E mutation was predominantly identified in FV-PTC, followed by FTC and PTC, and only one case of TA had the BRAF K601E mutation. Although it may affect the PI3k/Akt pathway, this mutation exhibited relatively inactive biological characteristics in the pathogenesis of TC compared with the BRAF V600E mutation (15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Moreover, in multifocal papillary thyroid carcinoma (mPTC), individual tumor foci may be identical and are frequently composed of various histological types, and individual tumor foci also harbor different mutations.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the prevalence of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) patients from eastern coastal China and to determine whether it is correlated with the clinicopathological features of PTCs with or without current Hashimoto thyroiditis (HT). The BRAF V600E mutation status was analyzed in 206 thyroid nodules of 154 patients undergoing thyroidectomy using polymerase chain reaction and bi-directional sequencing. Multivariate analysis was performed to investigate the association of the BRAF V600E mutation with clinicopathological features. Thyroid nodules were classified as PTC, nodular goiter (NG), adenomatoid nodule, adenoma and HT. The BRAF V600E mutation was observed in 61.5% of PTCs analyzed; it was also detected in one normal tissue adjacent to PTC and one NG. One patient exhibited double mutations in the BRAF gene; the BRAF V600E mutation in the PTC lesion and the BRAF K601E mutation in the contralateral NG lesion. Patients harboring the BRAF V600E mutation had higher thyroid stimulating hormone levels (2.453±1.464 vs. 1.966±1.296 mIU/l), a reduced occurrence of papillary thyroid microcarcinoma (55.0 vs. 88%), and a higher occurrence of lymph node metastasis (LNM; 42.5 vs. 16.0%) compared with those with wild-type BRAF (all P<0.05). Binary logistic regression analysis revealed that the BRAF V600E mutation was associated with LNM of PTC (hazard ratio, 5.051; 95% confidence interval, 1.068-23.893; P= 0.041). Conversely, no association was identified between the BRAF V600E mutation and HT (38.5 vs. 67.3%, χ 2 =3.656, P=0.056). Thus, in regional PTCs, the BRAF V600E mutation was prevalent, suggesting that it may be an early and phenotypically defining molecular event in PTC, and may represent an independent factor that predicts LNM.

show abstract

Expression of Benign and Malignant Thyroid Tissue in Ovarian Teratomas and the Importance of Multimodal Management as Illustrated by a BRAF-Positive Follicular Variant of Papillary Thyroid Cancer

Cited by 45 publications

References 36 publications

Clinicopathological relevance of BRAF mutations in human cancer

Clinicopathological relevance of BRAF mutations in human cancer

Abnormal radioiodine uptake on post-therapy whole body scan and sodium/iodine symporter expression in a dermoid cyst of the ovary: report of a case and review of the literature

Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules

Contact Info

Product

Resources

About